Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients With Hematologic Malignancies (HM)
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Orca-Q (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 11 Oct 2024 Status changed from discontinued to recruiting.
- 11 Jun 2024 Status changed from recruiting to discontinued.
- 29 Sep 2023 Status changed from suspended to recruiting.